<<snip>>
after only 2 weeks, PI may have a comparable therapeutic value to niacin
<<snip>>

J Lipid Res. 2004 Dec 1; [Epub ahead of print] Related Articles, Links  

 
Phosphatidylinositol raises HDL cholesterol levels in humans.

Burgess JW, Neville TA, Rouillard P, Harder Z, Beanlands DS, Sparks DL.

Studies have shown that phosphatidylinositol (PI) can stimulate reverse
cholesterol transport by enhancing the flux of cholesterol into HDL and by
promoting the transport of HDL-cholesterol to the liver and bile. The goal of
this study was to determine the safety and therapeutic value of PI following
oral administration to normolipidemic human subjects. We performed a randomized
2 week study in 16 normolipidemic subjects. Subjects received either 2.8 g or
5.6 g of PI, with or without food. PI was well tolerated by all subjects. PI
significantly affected the levels of HDL-C and triglyceride in the plasma of
subjects receiving PI with food. The lower dose showed a 13% increase in HDL-C,
while those on the high dose showed an increase of 18% over the 2 week period.
Both low and high dose groups showed significant elevations in plasma apoA-I.
The high dose of PI also decreased plasma triglycerides by 36% in the fed
subjects. The data suggest that after only 2 weeks, PI may have a comparable
therapeutic value to niacin, with negligible side effects.

PMID: 15576836 [PubMed - as supplied by publisher]

--------------------------------------------------------------------------
------

Who loves ya.
Tom